Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Investment Securities (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Gains from Investment Securities for 5 consecutive years, with $658563.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 92.58% to $658563.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $658563.0, a 92.58% decrease, with the full-year FY2025 number at $658563.0, down 92.58% from a year prior.
  • Gains from Investment Securities was $658563.0 for Q4 2025 at Janux Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $10.0 million in Q1 2025 to a low of -$1.1 million in Q3 2023.
  • A 5-year average of $2.0 million and a median of $759000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 764.13% in 2023, then skyrocketed 66533.76% in 2025.
  • Janux Therapeutics' Gains from Investment Securities stood at -$294000.0 in 2021, then surged by 217.01% to $344000.0 in 2022, then skyrocketed by 120.64% to $759000.0 in 2023, then soared by 1069.05% to $8.9 million in 2024, then plummeted by 92.58% to $658563.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Gains from Investment Securities are $658563.0 (Q4 2025), $1.7 million (Q3 2025), and $1.6 million (Q2 2025).